Hybridoma cell for resisting URG4 monoclonal antibody
A technology of hybridoma cells and hybridoma cell lines, applied in the field of hybridoma cells that can stably secrete anti-URG4 monoclonal antibody
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment Construction
[0014] 1 Materials and Instruments
[0015] 1.1 Cell lines, tissue samples and animals
[0016] a. Myeloma cells (SP2 / 0) were obtained from the Department of Immunology, Fourth Military Medical University.
[0017] b. The cell lines HepG2-Pc, HepG2-HBx, 3T3, 3T3-URG4, MKN28 are preserved in our institute.
[0018] c. Tissue source: Cases operated in Xijing Hospital from 2002 to 2004, diagnosed by pathology.
[0019] d. BALB / c mice: Experimental Animal Center of Fourth Military Medical University.
[0020] 1.2 Main reagents
[0021] a. Freund's complete adjuvant, Freund's incomplete adjuvant, HAT, HT, ABTS, PEG (molecular weight 4000), anti-β-actin monoclonal antibody, diethyl pyrocarbonate (DEPC) and ethidium bromide (EB) : Sigma Corporation;
[0022] b. HRP-labeled rabbit anti-mouse IgG: Percin Company;
[0023] c. RPMI1640 medium: HyClone company;
[0024] d. Cellulose acetate membrane (NC): Hybond company;
[0025] e. Calf serum: Hangzhou Sijiqing Bioengineering Mat...
PUM

Abstract
Description
Claims
Application Information

- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com